126 related articles for article (PubMed ID: 34917730)
21. 'Earlier than Early' Detection of Breast Cancer in Israeli
Anaby D; Shavin D; Zimmerman-Moreno G; Nissan N; Friedman E; Sklair-Levy M
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370730
[TBL] [Abstract][Full Text] [Related]
22. Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
Pilewskie M; Zabor EC; Gilbert E; Stempel M; Petruolo O; Mangino D; Robson M; Jochelson MS
Breast Cancer Res Treat; 2019 May; 175(1):141-148. PubMed ID: 30673971
[TBL] [Abstract][Full Text] [Related]
23. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
24. Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.
Jernigan AM; Mahdi H; Rose PG
Int J Gynecol Cancer; 2015 Sep; 25(7):1232-8. PubMed ID: 26067864
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience.
Cortesi L; Turchetti D; Marchi I; Fracca A; Canossi B; Rachele B; Silvia R; Rita PA; Pietro T; Massimo F
BMC Cancer; 2006 Aug; 6():210. PubMed ID: 16916448
[TBL] [Abstract][Full Text] [Related]
27. The BRCA Gene in Epithelial Ovarian Cancer.
Sánchez-Lorenzo L; Salas-Benito D; Villamayor J; Patiño-García A; González-Martín A
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267543
[TBL] [Abstract][Full Text] [Related]
28. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
30. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
[TBL] [Abstract][Full Text] [Related]
31. Multicenter cross-sectional screening of the
Wei H; Wang M; Ou J; Jiang W; Tian F; Sheng Y; Li H; Xu H; Zhang R; Guan A; Wang C; Jiang H; Ren Y; He J; Liu J; Huang W; Liao N; Cai X; Ming J; Ling R; Xu Y; Hu C; Zhang J; Guo B; Ouyang L; Shuai P; Liu Z; Zhong L; Jing R; Zeng Z; Zhang M; Zhang T; Xuan Z; Tan X; Liang J; Pan Q; Chen L; Zhang F; Fan L; Zhang Y; Yang X; Li J; Chen C; Jiang J
Oncol Lett; 2018 Jun; 15(6):9420-9428. PubMed ID: 29805665
[TBL] [Abstract][Full Text] [Related]
32. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract][Full Text] [Related]
33. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
34.
Manchana T; Phoolcharoen N; Tantbirojn P
Gynecol Oncol Rep; 2019 Aug; 29():102-105. PubMed ID: 31467961
[TBL] [Abstract][Full Text] [Related]
35. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
36. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
[TBL] [Abstract][Full Text] [Related]
37. [SCREENING WOMEN AT HIGH RISK FOR BREAST CANCER - BRCA AND BEYOND].
Hermann N; Westergard S; McCready DR
Harefuah; 2022 Feb; 161(2):95-100. PubMed ID: 35195970
[TBL] [Abstract][Full Text] [Related]
38. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
39. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
